LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma

Journal of Surgical Oncology

Volumn 101, Issue 5, 2010, Pages 363-369

  Yang, Hua ^a   Xiong, Fuxia ^a   Qi, Ruizhao ^b   Liu, Zhenwen ^b   Lin, Ming ^a   Rui, Jingan ^b   Su, Jing ^a   Zhou, Rouli ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b BEIJING 302 HOSPITAL   (China)

Author keywords

Hepatocellular carcinoma (HCC); Immunohistochemistry (IHC); Lysosomal protein transmembrane 4 beta (LAPTM4B); Prognosis; Western blot

Indexed keywords

LYSOSOMAL PROTEIN TRANSMEMBRANE 4 BETA; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME;

ADULT; ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; ONCOGENE PROTEINS; PROGNOSIS;

EID: 77950522449     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21489     Document Type: Article

References (25)

1. Howe HL,Wingo PA, Thun MJ, et al.: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824-842.
2. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
3. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
4. Landis SH, Murray T, Bolden S, et al.: Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
5. Shao GZ, Zhou RL, Zhang QY, et al.: Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 2003;22:5060-5069.
6. Liu X, Xiong F, Wei X, et al.: LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Sci 2009;100:2335-2340.
7. Zhou L, Rui JA, Ye DX, et al.: Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. World J Surg 2008;32:1748-1756.
8. Yang Y, Yang H, McNutt MA, et al.: LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep 2008;20:1077-1083.
9. Terentiev AA, Moldogazieva NT: Structural and functional mapping of alpha-fetoprotein. Biochemistry (Mosc) 2006;71: 120-132.
10. Zhou L, Liu J, Luo F: Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006;12:1175-1181.
11. Marrero JA, Su GL, Wei W, et al.: Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003;37:1114-1121.
12. Kladney RD, Cui X, Bulla GA, et al.: Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology 2002;35:1431-1440.
13. Gomaa AI, Khan SA, Leen EL, et al.: Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009;15:1301-1314.
14. Perugorria MJ, Castillo J, Latasa MU, et al.:Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy. Cancer Res 2009;69:1358-1367.
15. Hughes RM: Strategies for cancer gene therapy. J Surg Oncol 2004;85:28-35.
16. Philip PA, Mahoney MR, Allmer C, et al.: Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657-6663.
17. Wilhelm S, Carter C, Lynch M, et al.: Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-844.
18. Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
19. Thomas MB, Morris JS, Chadha R, et al.: Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843-850.
20. Thomas M: Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol 2009;44:136-141.
21. Vorhies JS, Nemunaitis J: Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies. Expert Rev Anticancer Ther 2007;7:373-382.
22. Yamamoto J, Kosuge T, Takayama T, et al.: Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996;83:1219-1222.
23. Chen XP, Qiu FZ,Wu ZD, et al.: Long-term outcome of resection of large hepatocellular carcinoma. Br J Surg 2006;93:600-606.
24. Riener MO, Stenner F, Liewen H, et al.: Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology 2009;49:1602-1609.
25. Logozzi M, De Milito A, Lugini L, et al.: High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One 2009;4:e5219.